Table 1.
Characteristics of the study population (n = 42).
| Variables | Mean ± standard deviation | Absolute frequency (%) |
|---|---|---|
| Age | ||
| Years | 62.21 ± 12.07 | – |
| Sex | ||
| Female | – | 25 (59.5) |
| Male | – | 17 (40.5) |
| BMI | ||
| kg/m2 | 26.88 ± 3.68 | – |
| Health condition | ||
| Hypertension | – | 39 (92.9) |
| Peripheral arterial disease | – | 15 (53.7) |
| Acute myocardial infarction | – | 12 (28.6) |
| CABS | – | 3 (7.1) |
| Coronary artery disease | – | 2 (4.8) |
| Heart transplantation | – | 2 (4.8) |
| Stroke | – | 2 (4.8) |
| Arrhythmia | – | 1 (2.4) |
| Valvulopathy | – | 1 (2.4) |
| Heart failure | – | 1 (2.4) |
| TGlittre | ||
| Seconds | 194.61 ± 44.81 | – |
| ISWT | ||
| Meters | 370 ± 135.72 | – |
| % predicted24 | 75.19 ± 23.89 | – |
| HAP | ||
| AAS | 68 ± 10.25 | – |
| Inactive | – | 3 (7.1) |
| Moderately active | – | 28 (66.7) |
| Active | – | 11 (26.2) |
| DASI | ||
| Score DASI | 37.83 ± 10.40 | – |
| Drugs | ||
| Statin | – | 34 (80.9) |
| Antiplatelets | – | 26 (61.9) |
| Beta-blocker | – | 22 (52.4) |
| ACE inhibitor | – | 16 (38.1) |
| AT1 receptor inhibitor | – | 13 (30.9) |
| Thiazide diuretic | – | 11 (26.2) |
| Calcium channel antagonist | – | 11 (26.2) |
| Loop diuretic | – | 7 (16.7) |
AAS, adjusted activity score; BMI, body mass index; CABS, coronary artery bypass surgery; DASI, Duke Activity Status Index; HAP, Human Activity Profile; ISWT, Incremental Shuttle Walking Test; TGlittre, Glittre ADL test runtime.